Table 1.
Treatment regimen | AUC (mg · h/liter) |
V/F (liters/kg) |
CL/F (liters/h) |
t1/2α (h) |
t1/2β (h) |
|||||
---|---|---|---|---|---|---|---|---|---|---|
Estimate | SE | Estimate | SE | Estimate | SE | Estimate | SE | Estimate | SE | |
6.25 mg/kg 1× | 15.71 | 0.44 | 1.54 | 0.18 | 0.40 | 0.01 | 1.19 | 0.36 | 6.05 | 0.54 |
6.25 mg/kg 5× | 16.82 | 0.94 | 0.65 | 0.24 | 0.37 | 0.02 | 0.44 | 0.19 | 7.06 | 0.62 |
12.5 mg/kg 1× | 38.37 | 0.94 | 0.78 | 0.08 | 0.33 | 0.01 | 0.76 | 0.12 | 6.14 | 0.29 |
12.5 mg/kg 5× | 34.29 | 2.15 | 0.58 | 0.15 | 0.36 | 0.02 | 0.40 | 0.15 | 6.52 | 0.60 |
Serum tigecycline levels were determined after administration of tigecycline at 6.25 mg/kg and 12.5 mg/kg in either a single dose (1×) or 5 consecutive doses (5×). Samples for pharmacokinetic analysis were taken (steady state) at 0.25, 0.5, 1, 2, 4, 6, 8, 20, and 24 h after the single administration or after the fifth dose of tigecycline. Concentration-time curves were analyzed using WinNonlin employing a two-compartment model. V, volume of distribution; CL, clearance; t1/2α, half-life at α phase; t1/2β, half-life at β phase; SE, standard error.